Cargando…
Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017882/ https://www.ncbi.nlm.nih.gov/pubmed/35439252 http://dx.doi.org/10.1371/journal.pone.0261932 |
| _version_ | 1784688878464008192 |
|---|---|
| author | Tajiri, Hitoshi Motoya, Satoshi Kinjo, Fukunori Maemoto, Atsuo Matsumoto, Takayuki Sato, Noriko Yamada, Hiroshi Nagano, Mieko Susuta, Yutaka Ozaki, Kunihiko Kondo, Kazuoki Hibi, Toshifumi |
| author_facet | Tajiri, Hitoshi Motoya, Satoshi Kinjo, Fukunori Maemoto, Atsuo Matsumoto, Takayuki Sato, Noriko Yamada, Hiroshi Nagano, Mieko Susuta, Yutaka Ozaki, Kunihiko Kondo, Kazuoki Hibi, Toshifumi |
| author_sort | Tajiri, Hitoshi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9017882 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90178822022-04-20 Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan Tajiri, Hitoshi Motoya, Satoshi Kinjo, Fukunori Maemoto, Atsuo Matsumoto, Takayuki Sato, Noriko Yamada, Hiroshi Nagano, Mieko Susuta, Yutaka Ozaki, Kunihiko Kondo, Kazuoki Hibi, Toshifumi PLoS One Correction Public Library of Science 2022-04-19 /pmc/articles/PMC9017882/ /pubmed/35439252 http://dx.doi.org/10.1371/journal.pone.0261932 Text en © 2022 Tajiri et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Tajiri, Hitoshi Motoya, Satoshi Kinjo, Fukunori Maemoto, Atsuo Matsumoto, Takayuki Sato, Noriko Yamada, Hiroshi Nagano, Mieko Susuta, Yutaka Ozaki, Kunihiko Kondo, Kazuoki Hibi, Toshifumi Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan |
| title | Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan |
| title_full | Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan |
| title_fullStr | Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan |
| title_full_unstemmed | Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan |
| title_short | Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan |
| title_sort | correction: infliximab for pediatric patients with crohn’s disease: a phase 3, open-label, uncontrolled, multicenter trial in japan |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017882/ https://www.ncbi.nlm.nih.gov/pubmed/35439252 http://dx.doi.org/10.1371/journal.pone.0261932 |
| work_keys_str_mv | AT tajirihitoshi correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT motoyasatoshi correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT kinjofukunori correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT maemotoatsuo correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT matsumototakayuki correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT satonoriko correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT yamadahiroshi correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT naganomieko correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT susutayutaka correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT ozakikunihiko correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT kondokazuoki correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan AT hibitoshifumi correctioninfliximabforpediatricpatientswithcrohnsdiseaseaphase3openlabeluncontrolledmulticentertrialinjapan |